Intraperitoneal chemotherapy for ovarian carcinoma: Results of long-term follow-up

被引:93
作者
Barakat, RR
Sabbatini, P
Bhaskaran, D
Revzin, M
Smith, A
Venkatraman, E
Aghajanian, C
Hensley, M
Soignet, S
Brown, C
Soslow, R
Markman, M
Hoskins, WJ
Spriggs, D
机构
[1] Mem Sloan Kettering Canc Ctr, Gynecol Serv Acad Off, Gynecol Dis Management Team, Dept Surg,Gynecol Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dynecol Dis Management Team, Dept Med, Dev Chemotherapy Serv, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dynecol Dis Management Team, Dept Biostat, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dynecol Dis Management Team, Dept Pathol, New York, NY 10021 USA
[5] Cleveland Clin, Ctr Canc, Dept Hematol Oncol, Cleveland, OH 44106 USA
关键词
D O I
10.1200/JCO.20.3.694
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose : To determine long-term survival and predictors of recurrence in a retrospective cohort of patients with epithelial ovarian cancer treated with intraperitoneal (113) chemotherapy. Patients and Methods: Records were reviewed of 433 patients who received IP therapy for ovarian cancer between 1984 and 1998; follow-up data were available for 411 patients. IP therapy was provided as consolidation therapy (n = 89), or for treatment of persistent (n = 310) or recurrent (n = 12) disease after surgery and initial systemic therapy; therapy usually consisted of platinum-based combination therapy. Statistical analysis included tests for associations between potential prognostic factors, and between prognostic factors and survival. Survival probabilities were estimated by Kaplan-Meier methods, and prognostic factors for survival were evaluated by a Cox proportional hazard model. Results: The mean age of patients was 52 years (range, 25 to 76 years). Distribution by stage and grade was as follows: stage 1, 7; 11, 24; 111, 342; IV, 52; not available (NA), 8; and grade 1, 30; 2, 99; and 3, 289; NA, 15. The median survival from initiation of IP therapy by residual disease was none, 8.7 years; microscopic, 4.8 years; less than 1 cm, 3.3 years; more than 1 cm, 1.2 years. In a multivariate analysis, the only significant predictors of long-term survival were grade and size of residual disease at initiation of IP therapy. Conclusion: Prolonged survival was observed in selected patients receiving IP platinum-based therapy. It is not possible to determine the contribution of IP therapy to survival in this study. A relationship between size of disease at the initiation of IP therapy and long-term survival was demonstrated. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:694 / 698
页数:5
相关论文
共 19 条
[1]   A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment [J].
Barakat, RR ;
Almadrones, L ;
Venkatraman, ES ;
Aghajanian, C ;
Brown, C ;
Shapiro, F ;
Curtin, JP ;
Spriggs, D .
GYNECOLOGIC ONCOLOGY, 1998, 69 (01) :17-22
[2]   Long-term results and prognostic factors in patients with epithelial ovarian cancer [J].
Brun, JL ;
Feyler, A ;
Chêne, G ;
Saurel, J ;
Brun, G ;
Hocké, C .
GYNECOLOGIC ONCOLOGY, 2000, 78 (01) :21-27
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   PHASE-I FEASIBILITY AND PHARMACOLOGICAL STUDY OF WEEKLY INTRAPERITONEAL PACLITAXEL - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY [J].
FRANCIS, P ;
ROWINSKY, E ;
SCHNEIDER, J ;
HAKES, T ;
HOSKINS, W ;
MARKMAN, M .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (12) :2961-2967
[5]   Cancer statistics, 2001 [J].
Greenlee, RT ;
Hill-Harmon, MB ;
Murray, T ;
Thun, M .
CA-A CANCER JOURNAL FOR CLINICIANS, 2001, 51 (01) :15-36
[6]   Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer [J].
Husain, A ;
Sabbatini, P ;
Spriggs, D ;
Fennelly, D ;
Aghajanian, C ;
Barakat, R ;
Curtin, J ;
Venkatraman, E ;
Hoskins, W ;
Markman, M .
GYNECOLOGIC ONCOLOGY, 1999, 73 (01) :96-101
[7]   The role of laparoscopy in second-look evaluations for ovarian cancer [J].
Husain, A ;
Chi, DS ;
Prasad, M ;
Abu-Rustum, N ;
Barakat, RR ;
Brown, CL ;
Poynor, EA ;
Hoskins, WJ ;
Curtin, JP .
GYNECOLOGIC ONCOLOGY, 2001, 80 (01) :44-47
[8]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[9]   Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy [J].
Lee, CK ;
de Miranda, MP ;
Ledermann, JA ;
de Elvira, MCR ;
Nelstrop, AE ;
Lambert, HE ;
Rustin, GJS ;
Trask, CWL .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (05) :727-732
[10]   Complications associated with intraperitoneal chemotherapy catheters [J].
Makhija, S ;
Leitao, M ;
Sabbatini, P ;
Bellin, N ;
Almadrones, L ;
Leon, L ;
Spriggs, DR ;
Barakat, R .
GYNECOLOGIC ONCOLOGY, 2001, 81 (01) :77-81